ReviewEuropean respiratory review : an official journal of the European Respiratory Society2021
Natural variability in the disease course of SSc-ILD: implications for treatment.
Review in European respiratory review : an official journal of the European Respiratory Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Pooled it
- Exploratory evaluation of earlyEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Review
- Predicting trajectories of lung function decline in systemic sclerosis-related interstitial lung disease.Rheumatology (Oxford, England) · 2025Article
- Fibrotic Disease of the Skin and Lung: Shared Pathways, Environmental Drivers, and Therapeutic Opportunities in a Changing Climate.International journal of molecular sciences · 2025Review
- Assessment of skin fibrosis in a murine model of systemic sclerosis with multifunctional optical coherence tomography.Journal of biomedical optics · 2025Article
- Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis.Rheumatology (Oxford, England) · 2024Article
- First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases.Biomedicines · 2024Article
- Experiences of systemic sclerosis patients with home monitoring of their pulmonary function: a qualitative study.Rheumatology advances in practice · 2024Article
- Article
- Treatable traits: a comprehensive precision medicine approach in interstitial lung disease.The European respiratory journal · 2023Article
- Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease.Expert review of clinical immunology · 2023Review
- Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience.Diagnostics (Basel, Switzerland) · 2023Article
- Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry.Biomedicines · 2022Article
- Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.Current rheumatology reports · 2022Review
- The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease.Therapeutic advances in musculoskeletal disease · 2022Review
- Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review.Therapeutic advances in musculoskeletal disease · 2022Review
- Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline.Frontiers in pharmacology · 2021Article
- Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts.Therapeutic advances in respiratory diseaseReview
- Incidence, prevalence and regional distribution of systemic sclerosis and related interstitial lung Disease: A nationwide retrospective cohort study.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung disease (ILD) affects approximately 50% of patients with systemic sclerosis (SSc) and is the leading cause of death in SSc. Our objective was to gain insight into the progression of SSc-associated ILD (SSc-ILD). Using data from longitudinal clinical trials and observational studies, we assessed definitions and patterns of progression, risk factors for progression, and implications for treatment. SSc-ILD progression was commonly defined as exceeding specific thresholds of lung function worsening and/or increasing radiographic involvement. One definition used in several studies is decline in forced vital capacity (FVC) of ≥10%, or ≥5-10% plus a decline in diffusing capacity of the lung for carbon monoxide ≥15%. Based on these criteria, 20-30% of patients in observational cohorts develop progressive ILD, starting early in the disease course and progressing at a highly variable rate.Risk factors such as age, FVC, extent of fibrosis and presence of anti-topoisomerase I antibodies can help predict progression of SSc-ILD, though composite risk scores may offer greater predictive power. Whilst the variability of the disease course in SSc-ILD makes risk stratification of patients challenging, the decision to initiate, change or stop treatment should be based on a combination of the current disease state and the speed of progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.